What goes wrong with microfracture alone in the hip

Microfracture starts with a sound idea. The surgeon drills or punches a series of small holes through the base of a cartilage defect into the subchondral bone beneath, releasing a concentrated mix of bone marrow blood and stem cells. That clot is supposed to consolidate and mature into repair tissue — and in the short term, it often does relieve pain and restore some function. The problem is what that repair tissue actually is.

The marrow clot predominantly generates type I collagen, producing fibrocartilage — a tissue closer in structure to scar than to the smooth, resilient type II hyaline cartilage that lines a healthy hip joint. Hyaline cartilage is engineered to transmit and distribute load across the femoral head and acetabulum for decades. Fibrocartilage is not. Under the repetitive shear forces of the hip, it degrades, and that degradation shows up reliably in the data: Kreuz and colleagues documented significant deterioration in patient-reported scores between 18 and 36 months post-operatively, while Solheim et al. recorded survivorship below 60% at three years, with a mean time to failure of approximately four years.

The hip creates an additional mechanical hazard that compounds this biological limitation. Synovial fluid circulates continuously through the joint, and the hip's range of motion generates substantial shear forces across the cartilage surface. The unprotected marrow clot — sitting open in the defect — is vulnerable to displacement and washout before it has time to consolidate. This problem is more pronounced in the hip than in the knee, where joint mechanics are less demanding on a freshly formed clot.

Repeated microfracture procedures carry a further cost: each pass through the subchondral bone plate can disrupt the calcified cartilage zone and alter the bone surface architecture, compromising the biological environment that more advanced techniques — such as AMIC or cell-based repair — depend upon. In practice, this means the window for more effective cartilage restoration may narrow with each failed attempt at marrow stimulation alone.

How AMIC fixes what microfracture cannot

The core fix is straightforward: cover the marrow clot before the hip joint can wash it away. AMIC does this by placing a bilayer collagen I/III membrane — Chondro-Gide — directly over the microfracture site at the moment the holes are made. That membrane acts as a biological roof, sealing the clot against the synovial fluid and shear forces that, in a standard microfracture procedure, cause it to displace before it has time to consolidate.

With the clot protected, the mesenchymal stem cells it contains remain concentrated at the defect site. The scaffold's architecture then plays a second role: it guides those cells toward hyaline-like type II cartilage rather than the fibrocartilage that unprotected clot typically produces. The distinction matters because hyaline-like tissue withstands the mechanical demands of the hip joint far better over the long term.

Patients sometimes worry that an implant placed inside the joint will remain there permanently. With Chondro-Gide, it does not. The membrane resorbs naturally over approximately four months, by which time the developing repair tissue beneath it has consolidated sufficiently to maintain its structure without support.

Because the scaffold is available off the shelf and is applied during a single operation, AMIC avoids the two-stage process required by autologous chondrocyte implantation (ACI) or its matrix-guided variant MACI. Those techniques require a first procedure to harvest cartilage cells, a laboratory culture period of several weeks, and a separate implantation operation. AMIC delivers scaffold-augmented repair in one sitting, with no cell-culture interval and no second procedure.

What the clinical evidence shows

The most comprehensive summary to date comes from a 2025 systematic review and meta-analysis of 628 hips across 12 studies. In that cohort — predominantly patients under 40 with focal defects averaging 3.3 cm², most treated in the context of FAI — AMIC achieved a pooled success rate of 99.6% and a mean improvement of 35.8 points on the modified Harris Hip Score, outperforming autologous chondrocyte transplantation in the same joint (31.1-point improvement; 98.3% success rate). Those figures relate to a specific patient profile — younger adults with focal, full-thickness lesions rather than diffuse arthritis — and should be understood as such.

The strongest direct comparison between AMIC and standalone microfracture comes from a 2016 arthroscopic study of 32 patients with cam-type FAI and acetabular lesions exceeding 150 mm². At roughly 38 to 41 months, the AMIC group reached a Harris Hip Score of 96.5 versus 93.5 for the microfracture group, with fewer conversions to total hip replacement (two versus three), significantly less post-operative synovitis, and higher rates of return to pre-injury sport.

Two independent mid-term cohorts extend the picture further. A five-year follow-up of nine patients (ten hips) recorded Oxford Hip Score improving from 38.1 to 43.4, UCLA activity score from 4 to 8.1, and a MOCART of 67.5, with no revision surgeries required. A separate Bone & Joint study at mean 6.2-year follow-up in 12 hips found Oxford Hip Score rising from 37.4 to 42.7 (p=0.014) and COMI declining from 4.1 to 1.6 (p=0.025), again with no patient converting to total hip arthroplasty. The AMIC Registry — 57 patients, mean age 37.3 years, mean defect 3.4 cm² — recorded statistically significant VAS pain reductions (p<0.001) and functional improvement at both one and two years.

The honest limitation is that virtually all hip AMIC data derive from small, single-centre cohorts without blinded controls. The directional consistency across multiple independent series and the registry is meaningful, but the evidence base remains built on case series rather than completed randomised trials.

Who is most likely to benefit from AMIC in the hip

The patients who tend to do well with AMIC share a fairly specific profile: under 50, with a focal, full-thickness cartilage lesion — ICRS grade III or IV — typically between 3 and 4 cm² in area. Lesions in that size range sit in a therapeutic gap: large enough that standalone microfracture consistently underperforms, yet not so extensive that they require an osteochondral allograft. Diffuse or advanced hip osteoarthritis sits outside this indication entirely — AMIC repairs discrete focal defects, not a joint that has lost cartilage broadly across multiple surfaces.

In clinical practice, almost all hip AMIC procedures are performed simultaneously with FAI osteoplasty correction. Cam or pincer morphology is the underlying mechanical cause of many focal acetabular and femoral head lesions, and correcting that impingement at the same operation is considered essential. The published outcomes described in the previous section reflect combined FAI correction and scaffold repair, not scaffold augmentation acting in isolation.

Recreational and competitive athletes with hip cartilage defects represent a group where the evidence is particularly encouraging. Published series suggest sustained functional benefit over the medium term and superior rates of return to pre-injury sport compared with standalone microfracture cohorts.

One practical consideration concerns timing. Prior microfracture can damage the subchondral bone plate in ways that may reduce the effectiveness of any subsequent cartilage repair procedure. That is a reason to seek a consultant opinion sooner rather than waiting to see whether an earlier marrow-stimulation procedure fully resolves symptoms on its own — early assessment preserves the most options.

What is still uncertain and what research is ongoing

Confidence in AMIC for hip cartilage repair is well-founded for the patient profile described above — but the evidence base is still maturing, and it is worth being clear about what has not yet been answered.

Long-term structural surveillance

The most instructive signal comes from MRI data. At mean 6.2-year follow-up, MOCART scores averaged 66.3 — acceptable repair tissue integration — but showed an inverse correlation with time (rs = −0.61, p = 0.035): in plain terms, images show gradual structural change in the repair tissue as years pass, even when patients continue to report meaningful functional gains. That dissociation between structural appearance and clinical outcome is reassuring for now, but it means ongoing monitoring matters. Whether the structural change eventually translates into clinical failure at the ten-year mark or beyond is not yet known, because hip-specific follow-up data beyond six to seven years remain sparse.

Defect size and lesion location

The procedures described in the literature have typically addressed lesions in the 3 to 4 cm² range. No study has formally established the upper size threshold beyond which AMIC in the hip ceases to confer durable benefit. Separately, almost all published data pool acetabular and femoral head lesions together; whether location within the hip joint materially affects outcome has not been disaggregated with sufficient numbers to answer confidently.

Augmentation alone is not enough

For context on what the scaffold is actually contributing, microfracture augmented with BioCartilage allograft cartilage and autologous PRP — biologic enhancement without a collagen membrane framework — still produced approximately 10% conversion to total hip arthroplasty at two years. That figure suggests that enriching the marrow stimulus without providing a physical scaffold to retain it offers incomplete protection, reinforcing the mechanistic case for the collagen membrane as the key structural element.

The REPAIR trial

The most consequential development for this field is the UK NHS HRA-registered REPAIR trial (NCT05402072) — the first dedicated randomised controlled trial to pit AMIC directly against standalone microfracture for acetabular cartilage defects of the hip, measuring hip function, health-related quality of life, and repair tissue quality. Completing that trial will be the step that moves AMIC from a consistently promising case-series technique to a procedure with guideline-level evidence behind it.

Hip preservation access and next steps in Lincolnshire

AMIC sits at the biological repair stage of the hip preservation pathway — typically considered after a period of conservative management and, where appropriate, injection support has been explored, and well before joint replacement becomes a realistic conversation. For patients under 50 with a confirmed focal full-thickness defect, pursuing a preservation approach is generally preferable to early arthroplasty: the aim is to restore tissue and delay or avoid replacement, not simply manage symptoms.

Seeking assessment at the right point matters. Prior marrow-stimulation procedures can compromise the subchondral bone plate and narrow future options, so early consultant opinion — rather than waiting on incomplete recovery — preserves the widest range of choices.

Specialist hip cartilage assessment does not require travelling to London. Lincolnshire Hip, with clinics in Sleaford and Grantham, offers consultant-led hip preservation assessment, and Prof Paul Y. F. Lee's clinical focus on biological repair techniques supports this pathway for patients across the region. Lincolnshire Hip is part of the MSK Doctors group and accepts patients without referral for hip assessment.

1. [1] A systematic review of surgical methods to restore articular cartilage in the hip. (2018). https://doi.org/10.1302/2046-3758.75.BJR-2017-0331 https://doi.org/10.1302/2046-3758.75.BJR-2017-0331
2. [2] Arthroscopic Treatment of Acetabular Cartilage Lesions in Cam-Type Hip Impingement with Membrane Induced Chondrogenesis versus Microfracturing. (2016). https://doi.org/10.17265/2332-7839/2016.01.002 https://doi.org/10.17265/2332-7839/2016.01.002
3. [3] Sustained benefit of autologous matrix-induced chondrogenesis for hip cartilage repair in a recreational athletic population. (2019). https://doi.org/10.1007/s00167-019-05801-y https://doi.org/10.1007/s00167-019-05801-y
4. [4] MID-TERM RESULTS OF AUTOLOGOUS MATRIX-INDUCED CHONDROGENESIS (AMIC) USED FOR LARGE CHONDRAL DEFECTS IN FEMOROACETABULAR IMPINGEMENT HIPS. (2023). https://doi.org/10.1302/1358-992x.2023.12.029 https://doi.org/10.1302/1358-992x.2023.12.029
5. [5] Patients Undergoing Microfracture With Allograft Cartilage and Autologous Platelet Rich Plasma Augmentation For Chondromalacia In The Hip Achieving High Rates Of Meaningful Outcomes At 2-Year Follow-Up. (2025). https://doi.org/10.1016/j.arthro.2025.01.022 https://doi.org/10.1016/j.arthro.2025.01.022